Metoprolol tartrate
ApprovedSmall molecule
Mylan Pharmaceuticals IncMetoprolol tartrate is one of 153 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
6
Indications
17
Total Trials
2
Active Trials
152
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Metoprolol tartrate
Mylan Pharmaceuticals IncApproved
Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Zebeta
TevaPreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Entresto
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertension3 trials
Black Education and Treatment of Hypertension (BEAT HTN)
Completed·—·Phase 4·NCT00661895·99 enrolled
ART3 trials
Coronary Artery Disease1 trial
Atrial Fibrillation1 trial
Rate Control in Atrial Fibrillation
Unknown status·—·Phase 4·NCT02251509·20 enrolled
8 more indications
Hypotensive Anesthesia1 trial
Is Labetalol More Effective Than Metoprolol for Controlled Hypotensive Anesthesia During Endoscopic Nasal Surgeries?
Completed·—·Phase 4·NCT05368376·60 enrolled
Septic Shock1 trial
Intravenous Metoprolol in Septic Shock
Completed·—·Phase 2·NCT06592547·100 enrolled
Traditional Medicine1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metoprolol tartrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company